Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Vpu binds directly to tetherin and displaces it from nascent virions.

McNatt MW, Zang T, Bieniasz PD.

PLoS Pathog. 2013;9(4):e1003299. doi: 10.1371/journal.ppat.1003299. Epub 2013 Apr 25.

2.

HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.

Pujol FM, Laketa V, Schmidt F, Mukenhirn M, Müller B, Boulant S, Grimm D, Keppler OT, Fackler OT.

J Virol. 2016 Jul 11;90(15):6709-23. doi: 10.1128/JVI.00504-16. Print 2016 Aug 1.

3.
4.

Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.

Lv M, Wang J, Wang X, Zuo T, Zhu Y, Kong W, Yu X.

PLoS One. 2011;6(6):e20890. doi: 10.1371/journal.pone.0020890. Epub 2011 Jun 2.

5.

Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Vigan R, Neil SJ.

J Virol. 2010 Dec;84(24):12958-70. doi: 10.1128/JVI.01699-10. Epub 2010 Oct 6.

6.

Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly.

Lewinski MK, Jafari M, Zhang H, Opella SJ, Guatelli J.

J Biol Chem. 2015 Apr 24;290(17):10919-33. doi: 10.1074/jbc.M114.630095. Epub 2015 Mar 10.

7.

Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.

Dotson D, Woodruff EA, Villalta F, Dong X.

J Biol Chem. 2016 Feb 19;291(8):4236-46. doi: 10.1074/jbc.M115.708123. Epub 2016 Jan 7.

8.

Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.

Jia X, Weber E, Tokarev A, Lewinski M, Rizk M, Suarez M, Guatelli J, Xiong Y.

Elife. 2014 Apr 29;3:e02362. doi: 10.7554/eLife.02362.

9.

β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.

Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT.

Retrovirology. 2011 Feb 10;8:9. doi: 10.1186/1742-4690-8-9.

10.

Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.

Lukhele S, Cohen ÉA.

Retrovirology. 2017 Mar 14;14(1):18. doi: 10.1186/s12977-017-0345-6.

11.

Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.

Rollason R, Dunstan K, Billcliff PG, Bishop P, Gleeson P, Wise H, Digard P, Banting G.

PLoS One. 2013 Sep 24;8(9):e75680. doi: 10.1371/journal.pone.0075680. eCollection 2013.

12.

Transmembrane interactions of HIV-1 Vpu and tetherin.

Guo F, Liang C.

Curr HIV Res. 2012 Jun;10(4):292-7. Review.

PMID:
22524177
13.

The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.

Kluge SF, Sauter D, Vogl M, Peeters M, Li Y, Bibollet-Ruche F, Hahn BH, Kirchhoff F.

Retrovirology. 2013 Mar 20;10:32. doi: 10.1186/1742-4690-10-32.

14.

Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.

Yoshida T, Koyanagi Y, Strebel K.

J Virol. 2013 Dec;87(24):13825-36. doi: 10.1128/JVI.02567-13. Epub 2013 Oct 9.

15.

HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.

Fritz JV, Tibroni N, Keppler OT, Fackler OT.

Virology. 2012 Mar 1;424(1):33-44. doi: 10.1016/j.virol.2011.12.008. Epub 2012 Jan 4.

16.
17.

Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.

Petit SJ, Blondeau C, Towers GJ.

J Gen Virol. 2011 Dec;92(Pt 12):2937-48. doi: 10.1099/vir.0.035931-0. Epub 2011 Sep 7.

18.

HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions.

Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, Stephens EB, Opella SJ, Guatelli J.

J Biol Chem. 2012 Jan 2;287(1):58-67. doi: 10.1074/jbc.M111.296772. Epub 2011 Nov 9.

19.

Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities.

Cocka LJ, Bates P.

PLoS Pathog. 2012 Sep;8(9):e1002931. doi: 10.1371/journal.ppat.1002931. Epub 2012 Sep 27.

20.

Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.

Nikovics K, Dazza MC, Ekwalanga M, Mammano F, Clavel F, Saragosti S.

PLoS One. 2012;7(4):e35411. doi: 10.1371/journal.pone.0035411. Epub 2012 Apr 17.

Supplemental Content

Support Center